Viveve Announces Positive Primary Efficacy Data from its SUI Feasibility Study and Positive Preclinical Outcomes that Support the Company's New Sham Tip for Pivotal PURSUIT Trial - BioSpace
[unable to retrieve full-text content] NAVIGATING THE SILENCE: RECONSIDERING TREATMENT PARADIGMS IN ASYMPTOMATIC SEVERE AORTIC STENOSIS ScienceDirect.com
Comments
Post a Comment